Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP7 | Q93009 | 14/20 | 1.00 |
| ▸ | USP47 | Q96K76 | 6/20 | 1.00 |
| ▸ | USP10 | Q14694 | 1/20 | 1.00 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.58 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | TTR | P02766 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2680945 | 1.00 | USP7 (1.00) | USP7USP47USP10PADI4ATM | |
| SCHEMBL2680882 | 0.89 | USP7 (0.80) | USP7USP47USP10PADI4ATM | |
| SCHEMBL2681306 | 0.87 | USP7 (0.77) | USP7USP47USP10PADI4ATM | |
| SCHEMBL2680442 | 0.79 | USP7 (0.65) | USP7USP47USP10PADI4 | |
| SCHEMBL2680726 | 0.78 | USP7 (1.00) | USP7USP47USP10PADI4TDP1 | |
| SCHEMBL25465158 | 0.78 | USP7 (0.63) | USP7USP47USP10PADI4KDM4E | |
| SCHEMBL21123615 | 0.78 | USP7 (0.63) | USP7USP47USP10PADI4ATM | |
| SCHEMBL2680611 | 0.77 | USP7 (0.71) | USP7USP47USP10PADI4TDP1 | |
| SCHEMBL2680825 | 0.77 | USP7 (1.00) | USP7USP47USP10PADI4TDP1 | |
| SCHEMBL17059890 | 0.76 | USP7 (1.00) | USP7USP47USP10ATMTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4691479-A2 | GENERATION OF HUMAN PLURIPOTENT STEM CELL DERIVED FUNCTIONAL BETA CELLS SHOWING A GLUCOSE-DEPENDENT MITOCHONDRIAL RESPIRATION AND TWO-PHASE INSULIN SECRETION RESPONSE | Janssen Biotech, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| EP-4194548-B1 | GENERATION OF HUMAN PLURIPOTENT STEM CELL DERIVED FUNCTIONAL BETA CELLS SHOWING A GLUCOSE-DEPENDENT MITOCHONDRIAL RESPIRATION AND TWO-PHASE INSULIN SECRETION RESPONSE | JANSSEN BIOTECH INC (US) | 2025-10-22 | — | — | EP | disclosed |
| US-20240417693-A1 | GENERATION OF HUMAN PLURIPOTENT STEM CELL DERIVED FUNCTIONAL BETA CELLS SHOWING A GLUCOSE-DEPENDENT MITOCHONDRIAL RESPIRATION AND TWO-PHASE INSULIN SECRETION RESPONSE | JANSSEN BIOTECH, INC. (US) | 2024-12-19 | — | — | US | disclosed |
| CN-118021824-B | Medicine for resisting Marek's disease virus and application of dandelion sterol or ferulic acid in preparation of medicine by combination | 吉林大学 | 2024-11-26 | — | — | CN | disclosed |
| CN-118078824-B | Anti-Marek's disease virus medicine and application of RA190 or glycyrrhizic acid and combined use thereof in preparation of medicine | 吉林大学 | 2024-11-08 | — | — | CN | disclosed |
| CN-118021772-B | Anti-Marek's disease virus medicine, resveratrol or chlorogenic acid and application of resveratrol or chlorogenic acid in combination in preparation of medicine | 吉林大学 | 2024-11-08 | — | — | CN | disclosed |
| WO-2024210503-A1 | COMPOSITION CONTAINING USP10 INHIBITOR AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF OBESITY AND LIPID-RELATED METABOLIC DISEASES | 연세대학교 산학협력단 | 2024-10-10 | — | — | WO | disclosed |
| WO-2024168301-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | FUNCTION ONCOLOGY, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| CN-118078824-A | Anti-Marek's disease virus medicine and application of RA190 or glycyrrhizic acid and combined use thereof in preparation of medicine | 吉林大学 | 2024-05-28 | — | — | CN | disclosed |
| CN-118021772-A | Anti-Marek's disease virus medicine, resveratrol or chlorogenic acid and application of resveratrol or chlorogenic acid in combination in preparation of medicine | 吉林大学 | 2024-05-14 | — | — | CN | disclosed |
| CN-118021824-A | Medicine for resisting Marek's disease virus and application of dandelion sterol or ferulic acid in preparation of medicine by combination | 吉林大学 | 2024-05-14 | — | — | CN | disclosed |
| US-11952591-B2 | Generation of human pluripotent stem cell derived functional beta cells showing a glucose-dependent mitochondrial respiration and two-phase insulin secretion response | JANSSEN BIOTECH, INC. (US) | 2024-04-09 | — | — | US | disclosed |
| US-20230203485-A1 | METHODS FOR MODULATING MHC-I EXPRESSION AND IMMUNOTHERAPY USES THEREOF | LEE PATRICK C (US) | 2023-06-29 | — | — | US | disclosed |
| EP-4194548-A1 | GENERATION OF HUMAN PLURIPOTENT STEM CELL DERIVED FUNCTIONAL BETA CELLS SHOWING A GLUCOSE-DEPENDENT MITOCHONDRIAL RESPIRATION AND TWO-PHASE INSULIN SECRETION RESPONSE | Janssen Biotech, Inc. (US) | 2023-06-14 | — | — | EP | disclosed |
| EP-4161658-A1 | METHODS FOR MODULATING MHC-I EXPRESSION AND IMMUNOTHERAPY USES THEREOF | Dana-Farber Cancer Institute, Inc. (US) | 2023-04-12 | — | — | EP | disclosed |
| EP-3472303-B1 | GENERATION OF HUMAN PLURIPOTENT STEM CELL DERIVED FUNCTIONAL BETA CELLS SHOWING A GLUCOSE-DEPENDENT MITOCHONDRIAL RESPIRATION AND TWO-PHASE INSULIN SECRETION RESPONSE | JANSSEN BIOTECH INC (US) | 2022-12-14 | — | — | EP | disclosed |
| CN-112972476-B | Medicament for inhibiting marek's disease virus replication and preventing or resisting marek's disease | 吉林大学 | 2022-04-29 | — | — | CN | disclosed |
| CN-113648337-B | Application of tripterine in preparation of medicine for inhibiting replication of Marek's disease virus | 吉林大学 | 2022-04-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11952591-B2 | Generation of human pluripotent stem cell derived functional beta cells showing a glucose-dependent mitochondrial respiration and two-phase insulin secretion response | SLC2A3, SLC2A2, SLC2A1 | USP7 1812/4885USP47 2306/4885USP10 1519/4885 |
| US-20230203485-A1 | METHODS FOR MODULATING MHC-I EXPRESSION AND IMMUNOTHERAPY USES THEREOF | MICA, CD74, HLA-DRB1 | USP7 2899/4885USP47 2575/4885USP10 3459/4885 |
| US-20240417693-A1 | GENERATION OF HUMAN PLURIPOTENT STEM CELL DERIVED FUNCTIONAL BETA CELLS SHOWING A GLUCOSE-DEPENDENT MITOCHONDRIAL RESPIRATION AND TWO-PHASE INSULIN SECRETION RESPONSE | SLC2A3, SLC2A2, SLC2A1 | USP7 1812/4885USP47 2306/4885USP10 1519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.